Last updated: May 27, 2026
MAYZENT (siponimod) is supplied in the US market by Novartis under branded distribution. The company’s supply chain centers on Novartis manufacturing and procurement for (1) siponimod active pharmaceutical ingredient (API), (2) drug product (tablet), and (3) packaging and distribution into FDA-controlled channels.
Who supplies MAYZENT siponimod tablets in the US market?
US branded supply is through Novartis. MAYZENT is marketed and distributed in the US by Novartis Pharmaceuticals Corporation.
What is the manufacturer listed for MAYZENT drug product?
Manufacturer (labeler of record) for the drug product is Novartis. For the specific US strength and pack configuration, the “Manufacturer”/“Distributed by” and “Manufactured for” lines on the current US package labeling reflect the responsible labeler and the manufacturing site(s) supporting commercialization.
What suppliers provide MAYZENT siponimod API and where is the API made?
API supply is through Novartis’s global supply chain. Siponimod API is sourced by Novartis from its upstream manufacturing network for GMP-compliant API production and release.
How is MAYZENT API typically sourced for global commercialization?
For branded oral therapies like siponimod, the API is generally produced via company-controlled or qualified third-party GMP facilities and released under Novartis quality systems. The relevant upstream site names and supplier contracts are reflected when disclosed in labeling, DMF referencing, or regulatory filings, but the public-facing supplier attribution for MAYZENT is predominantly Novartis.
Which companies are the manufacturing or fill-finish suppliers for MAYZENT tablets?
Public supplier attribution for manufacturing and packaging is Novartis. For MAYZENT, the public record commonly identifies Novartis as the “manufactured for” or “distributed by” entity, with additional site identifiers tied to batch release manufacturing locations in US product labeling.
What dose forms and packaging drive supplier qualification?
- Oral solid dose: tablets
- Strength variants: per current labeling availability
- Packaging format: bottles or cartons per NDC presentation
Supplier qualification for packaging and tablet manufacture is tied to the NDC-specific product listing and labeled manufacturing sites.
What is the FDA regulatory status of MAYZENT that shapes supplier controls?
MAYZENT is an FDA-approved brand product with a listed New Drug Application (NDA) and drug product labeling that controls manufacturing and supply chain release. The FDA regulatory status governs:
- API and finished product GMP release
- batch record compliance and CMC controls
- handling of changes to manufacturing sites and processes
How does the NDA structure affect who can supply the drug?
Drug supply is constrained by NDA drug product CMC. New suppliers for API or tablet manufacture typically require:
- changes to the NDA manufacturing description
- comparability for process/site changes
- inspection clearance for the new facility
How do US supply and EU supply differ for MAYZENT?
The supplier set is branded and jurisdictional. In practice:
- US distribution is anchored to Novartis US labeler/manufacturer declarations.
- EU supply involves Novartis entities and may use different labeled manufacturing sites depending on local marketing authorizations and NDC-equivalent product packaging.
Public visibility into site-level supplier lists is usually less granular than the “responsible labeler” entity unless a site change triggers updated labeling with the new manufacturing location.
What does the Orange Book say about MAYZENT suppliers or manufacturing?
Orange Book listing addresses patents and exclusivity, not supplier contracts. The Orange Book identifies:
- NDA number
- Orange Book patent and exclusivity information
- whether exclusivity blocks generic entry
It does not publish upstream API supplier names for MAYZENT. Supplier identities in public domains usually come from labeling, facility registrations, or dossier content in filings such as DMFs, which may not enumerate commercial suppliers by name publicly.
What generic or biosimilar entry risk affects MAYZENT supply planning?
Siponimod is a small-molecule oral therapy. The principal generic entry path is through ANDAs and Paragraph IV certifications against listed patents. Supplier risk for Novartis supply planning increases when:
- generics gain approval
- authorized generics or multiple generic products enter
- contract manufacturing and procurement shift to support demand volatility
Public supplier names for generic entrants vary by ANDA applicant and their chosen API and finished-goods partners.
Supplier landscape by supply chain layer for MAYZENT
| Supply-chain layer |
Typical public attribution for MAYZENT |
Example entities (publicly recognized) |
| Drug product labeler/distributor |
Branded marketing authorization holder and labeler |
Novartis |
| Tablet manufacturing |
Labeled “manufactured for” or site listed in labeling |
Novartis-linked GMP sites |
| Packaging/labeling |
Labeled packaging and manufacturing controls under NDA |
Novartis-linked operations |
| API supplier |
Upstream GMP API production via qualified network |
Novartis procurement/manufacturing network |
Key takeaways
- Novartis is the public-facing supplier for MAYZENT distribution and drug product responsibility in the US.
- Upstream siponimod API sourcing and tablet manufacturing occur under Novartis quality and regulatory controls, with site details reflected in product labeling and regulatory submissions rather than broadly published third-party supplier rosters.
- Orange Book content focuses on patents and exclusivity, not API or fill-finish supplier contract identities.
FAQs
1) Who is the labeler/distributor for MAYZENT in the US?
Novartis is the responsible branded labeler/distributor for MAYZENT in the US product labeling.
2) Are there publicly named third-party suppliers for MAYZENT API?
Publicly, supplier attribution is predominantly Novartis-linked; third-party API supplier names are not typically enumerated in standard public references.
3) Does the Orange Book list MAYZENT manufacturing sites or suppliers?
No. The Orange Book lists patents and exclusivity tied to the NDA, not manufacturing supplier contracts or site rosters.
4) What drives changes in MAYZENT manufacturing supplier or site?
FDA CMC supplements and comparability/inspection readiness for new API or finished-goods manufacturing sites.
5) Who supplies MAYZENT outside the US?
Supply is still generally Novartis-controlled, with jurisdiction-specific labeling and manufacturing site declarations tied to local product authorizations.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (MAYZENT/siponimod). US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drugs@FDA: MAYZENT (siponimod). US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- Novartis. MAYZENT (siponimod) US Prescribing Information and US package labeling.
